Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer beyond PARP inhibitors. Cancer Discov. 2017;7:20–37.
Google Scholar
Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220–8.
Google Scholar
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8.
Google Scholar
Chang HH, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18:495–506.
Google Scholar
Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47:497–510.
Google Scholar
Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.
Google Scholar
Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78–94.
Google Scholar
Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–98.
Google Scholar
Gogola E, Rottenberg S, Jonkers J. Resistance to PARP inhibitors: lessons from preclinical models of BRCA-associated cancer. Annu Rev Cancer Biol. 2019;3:235–54.
Google Scholar
Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002;62:219–25.
Google Scholar
Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011;17:88–96.
Google Scholar
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.
Google Scholar
Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9:338–50.
Google Scholar
Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.
Google Scholar
Bian L, Meng Y, Zhang M, Li D. MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Mol Cancer. 2019;18:169.
Google Scholar
Huertas P, Jackson SP. Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J Biol Chem. 2009;284:9558–65.
Google Scholar
Anand R, Ranjha L, Cannavo E, Cejka P. Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. Mol Cell. 2016;64:940–50.
Google Scholar
Stracker TH, Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol. 2011;12:90–103.
Google Scholar
Garcia V, Phelps SE, Gray S, Neale MJ. Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1. Nature. 2011;479:241–4.
Google Scholar
Zhang T, Yang H, Zhou Z, Bai Y, Wang J, Wang W. Crosstalk between SUMOylation and ubiquitylation controls DNA end resection by maintaining MRE11 homeostasis on chromatin. Nat Commun. 2022;13:5133.
Google Scholar
Cejka P, Symington LS. DNA end resection: mechanism and control. Annu Rev Genet. 2021;55:285–307.
Google Scholar
Jachimowicz RD, Beleggia F, Isensee J, Velpula BB, Goergens J, Bustos MA, et al. UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors. Cell. 2019;176:505–19.e22.
Google Scholar
Belmonte-Fernández A, Herrero-Ruíz J, Galindo-Moreno M, Limón-Mortés MC, Mora-Santos M, Sáez C, et al. Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway. Cell Death Differ. 2023;30:488–99.
Google Scholar
Nicholson J, Jevons SJ, Groselj B, Ellermann S, Konietzny R, Kerr M, et al. E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer. Cancer Res. 2017;77:3027–39.
Google Scholar
Sanchez-Bailon M, Choi S, Dufficy E, Sharma K, McNee G, Gunnell E, et al. Arginine methylation and ubiquitylation crosstalk controls DNA end-resection and homologous recombination repair. Nat Commun. 2021;12:6313.
Google Scholar
Yu Z, Vogel G, Coulombe Y, Dubeau D, Spehalski E, Hébert J, et al. The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation. Cell Res. 2012;22:305–20.
Google Scholar
Chen Y, Wu J, Zhai L, Zhang T, Yin H, Gao H, et al. Metabolic regulation of homologous recombination repair by MRE11 lactylation. Cell. 2024;187:294–311.e21.
Google Scholar
Zeng X, Zhao F, Cui G, Zhang Y, Deshpande RA, Chen Y, et al. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Nat Cancer. 2022;3:1088–104.
Google Scholar
Bai Y, Wang W, Li S, Zhan J, Li H, Zhao M, et al. C1QBP promotes homologous recombination by stabilizing MRE11 and controlling the assembly and activation of the MRE11/RAD50/NBS1 complex. Mol Cell. 2019;75:1299–1314.e6.
Google Scholar
Liu W, Zheng M, Zhang R, Jiang Q, Du G, Wu Y, et al. RNF126-mediated MRE11 ubiquitination activates the DNA damage response and confers resistance of triple-negative breast cancer to radiotherapy. Adv Sci. 2023;10:2203884.
Google Scholar
Chicca JJ, Auble DT, Pugh BF. Cloning and biochemical characterization of TAF-172, a human homolog of yeast Mot1. Mol Cell Biol. 1998;18:1701–10.
Google Scholar
Pereira LA, Klejman MP, Timmers HTM. Roles for BTAF1 and Mot1p in dynamics of TATA-binding protein and regulation of RNA polymerase II transcription. Gene. 2003;315:1–13.
Google Scholar
Pereira LA, Klejman MP, Ruhlmann C, Kavelaars F, Oulad-Abdelghani M, Timmers HTM, et al. Molecular architecture of the basal transcription factor B-TFIID. J Biol Chem. 2004;279:21802–7.
Google Scholar
Klejman MP, Zhao X, van Schaik FM, Herr W, Timmers HTM. Mutational analysis of BTAF1-TBP interaction: BTAF1 can rescue DNA-binding defective TBP mutants. Nucleic Acids Res. 2005;33:5426–36.
Google Scholar
Butryn A, Schuller JM, Stoehr G, Runge-Wollmann P, Förster F, Auble DT, et al. Structural basis for recognition and remodeling of the TBP:DNA:NC2 complex by Mot1. eLife. 2015;4:e07432.
Google Scholar
Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011;17:12–20.
Google Scholar
Olivieri M, Cho T, Álvarez-Quilón A, Li K, Schellenberg MJ, Zimmermann M, et al. A genetic map of the response to DNA damage in human cells. Cell. 2020;182:481–96.e21.
Google Scholar
van der Knaap JA, van den Boom V, Kuipers J, van Eijk MJ, van der Vliet PC, Timmers HTM. The gene for human TATA-binding-protein-associated factor (TAFII) 170: structure, promoter and chromosomal localization. Biochem J. 2000;345:521–7.
Google Scholar
van der Knaap JA, Borst JW, van der Vliet PC, Gentz R, Timmers HTM. Cloning of the cDNA for the TATA-binding protein-associated factorII170 subunit of transcription factor B-TFIID reveals homology to global transcription regulators in yeast and Drosophila. Proc Natl Acad Sci USA. 1997;94:11827–32.
Google Scholar
Pereira LA, van der Knaap JA, van den Boom V, van den Heuvel FA, Timmers HTM. TAFII170 interacts with the concave surface of TATA-binding protein to inhibit its DNA binding activity. Mol Cell Biol. 2001;21:7523–34.
Google Scholar
Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18:99–113.
Google Scholar
Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610–21.
Google Scholar
Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360–94.
Google Scholar
Lo Monte M, Manelfi C, Gemei M, Corda D, Beccari AR. ADPredict: ADP-ribosylation site prediction based on physicochemical and structural descriptors. Bioinformatics. 2018;34:2566–74.
Google Scholar
Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287–94.
Google Scholar
